Click Here for 5% Off Your First Aladdin Purchase!

Riluzole - ≥98%, high purity , Sodium channel alpha subunit blocker, CAS No.1744-22-5, Sodium channel alpha subunit blocker

  • Moligand™
  • ≥98%
Item Number
R129533
Grouped product items
SKUSizeAvailabilityPrice Qty
R129533-1g
1g
In stock
$205.90
R129533-5g
5g
In stock
$927.90
R129533-25g
25g
In stock
$4,171.90
R129533-100g
100g
In stock
$15,017.90

Basic Description

Synonymsriluzole|1744-22-5|Rilutek|2-Amino-6-(trifluoromethoxy)benzothiazole|6-(trifluoromethoxy)benzo[d]thiazol-2-amine|6-(trifluoromethoxy)-1,3-benzothiazol-2-amine|RP-54274|Riluzolum|Riluzol|2-amino-6-trifluoromethoxybenzothiazole|2-Benzothiazolamine, 6-(trifl
Specifications & PurityMoligand™, ≥98%
Biochemical and Physiological MechanismsGlutamate release inhibitor; anticonvulsant
Shipped InNormal
GradeMoligand™
Action TypeACTIVATOR, BLOCKER, CHANNEL BLOCKER, GATING INHIBITOR
Mechanism of actionSodium channel alpha subunit blocker
Product Description

Riluzole is a drug used to treat amyotrophic lateral sclerosis.

Product Properties

ALogP3.6

Associated Targets

CYP1A2 Tchem Cytochrome P450 1A2 2 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

DRD2 Tclin D(2) dopamine receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

DRD4 Tchem D(4) dopamine receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CYP3A4 Tclin Cytochrome P450 3A4 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ERBB2 Tclin Receptor tyrosine-protein kinase erbB-2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

GABRA1 Tclin Gamma-aminobutyric acid receptor subunit alpha-1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ELANE Tclin Neutrophil elastase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

EGFR Tclin Epidermal growth factor receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HMGCR Tclin 3-hydroxy-3-methylglutaryl-coenzyme A reductase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HDAC6 Tclin Histone deacetylase 6 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HRH1 Tclin Histamine H1 receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

SLCO1B3 Tchem Solute carrier organic anion transporter family member 1B3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

SLC6A4 Tclin Sodium-dependent serotonin transporter 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

SIGMAR1 Tclin Sigma non-opioid intracellular receptor 1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PDE4D Tclin cAMP-specific 3',5'-cyclic phosphodiesterase 4D 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PTGS1 Tclin Prostaglandin G/H synthase 1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CA2 Tclin Carbonic anhydrase 2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

DRD3 Tclin D(3) dopamine receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CHRM3 Tclin Muscarinic acetylcholine receptor M3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CHRM4 Tclin Muscarinic acetylcholine receptor M4 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADRA2B Tclin Alpha-2B adrenergic receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADRA2C Tclin Alpha-2C adrenergic receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HTR2A Tclin 5-hydroxytryptamine receptor 2A 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADORA2A Tclin Adenosine receptor A2a 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ACHE Tclin Acetylcholinesterase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADRA1A Tclin Alpha-1A adrenergic receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

AR Tclin Androgen receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

AKR1B1 Tclin Aldose reductase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADORA1 Tclin Adenosine receptor A1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HTR1A Tclin 5-hydroxytryptamine receptor 1A 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADORA3 Tchem Adenosine receptor A3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HTR3A Tclin 5-hydroxytryptamine receptor 3A 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HTR6 Tchem 5-hydroxytryptamine receptor 6 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HTR2B Tclin 5-hydroxytryptamine receptor 2B 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

F2 Tclin Prothrombin 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

EDNRA Tclin Endothelin-1 receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

KCNK2 Tclin Potassium channel subfamily K member 2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

KCND3 Tclin Potassium voltage-gated channel subfamily D member 3 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

KCNH2 Tclin Potassium voltage-gated channel subfamily H member 2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

OPRD1 Tclin Delta-type opioid receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

OPRK1 Tclin Kappa-type opioid receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

OPRM1 Tclin Mu-type opioid receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

NOS2 Tchem Nitric oxide synthase, inducible 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

TACR1 Tclin Substance-P receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

KCND2 Tclin Potassium voltage-gated channel subfamily D member 2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

NOS1 Tchem Nitric oxide synthase, brain 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

Pubchem Sid488179874
Pubchem Sid Urlhttps://pubchem.ncbi.nlm.nih.gov/substance/488179874
IUPAC Name 6-(trifluoromethoxy)-1,3-benzothiazol-2-amine
INCHI InChI=1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)
InChi Key FTALBRSUTCGOEG-UHFFFAOYSA-N
Canonical SMILES C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N
Isomeric SMILES C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N
WGK Germany 3
RTECS DL2830000
PubChem CID 5070
Molecular Weight 234.2

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

10 results found

Lot NumberCertificate TypeDateItem
J22111427Certificate of AnalysisJul 10, 2024 R129533
J22111435Certificate of AnalysisJul 10, 2024 R129533
J22111436Certificate of AnalysisJul 10, 2024 R129533
J2212054Certificate of AnalysisJul 10, 2024 R129533
F1502089Certificate of AnalysisJan 25, 2023 R129533
C2116156Certificate of AnalysisJan 11, 2023 R129533
C2116157Certificate of AnalysisJan 11, 2023 R129533
C2116158Certificate of AnalysisJan 11, 2023 R129533
D23261188Certificate of AnalysisAug 25, 2022 R129533
H2212229Certificate of AnalysisAug 25, 2022 R129533

Chemical and Physical Properties

SolubilityDMSO 47 mg/mL Water Ethanol 47 mg/mL
Melt Point(°C)118 °C

Safety and Hazards(GHS)

Pictogram(s) GHS06
Signal Danger
Hazard Statements

H301:Toxic if swallowed

Precautionary Statements

P321:Specific treatment (see ... on this label).

P405:Store locked up.

P501:Dispose of contents/container to ...

P264:Wash hands [and …] thoroughly after handling.

P270:Do not eat, drink or smoke when using this product.

P330:Rinse mouth.

P301+P316:IF SWALLOWED: Get emergency medical help immediately.

WGK Germany 3
RTECS DL2830000
Merck Index 8223

Related Documents

References

1. Mostert JP, Koch MW, Heerings M, Heersema DJ, De Keyser J.  (2008)  Therapeutic potential of fluoxetine in neurological disorders..  CNS Neurosci Ther,  14  (2): (153-64).  [PMID:18482027]
2. Killestein J, Kalkers NF, Polman CH.  (2005)  Glutamate inhibition in MS: the neuroprotective properties of riluzole..  J Neurol Sci,  233  (1-2): (113-5).  [PMID:15949499]
3. Arun T, Tomassini V, Sbardella E, de Ruiter MB, Matthews L, Leite MI, Gelineau-Morel R, Cavey A, Vergo S, Craner M et al..  (2013)  Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride..  Brain,  136  (Pt 1): (106-15).  [PMID:23365093]
4. Mostert J, Heersema T, Mahajan M, Van Der Grond J, Van Buchem MA, De Keyser J.  (2013)  The effect of fluoxetine on progression in progressive multiple sclerosis: a double-blind, randomized, placebo-controlled trial..  ISRN Neurol,  2013  (3): (370943).  [PMID:23984093]
5. Huang CS, Song JH, Nagata K, Yeh JZ, Narahashi T.  (1997)  Effects of the neuroprotective agent riluzole on the high voltage-activated calcium channels of rat dorsal root ganglion neurons..  J Pharmacol Exp Ther,  282  (3): (1280-90).  [PMID:9316836]

Solution Calculators